ABBV Jan 2025 220.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:12PM EST. Market open.
| Previous close | 0.2000 |
| Open | 0.1200 |
| Bid | 0.0700 |
| Ask | 0.2500 |
| Strike | 220.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.1200 - 0.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 83 |
Simply Wall St.AbbVie (NYSE:ABBV) Has Announced That It Will Be Increasing Its Dividend To $1.55
AbbVie Inc. ( NYSE:ABBV ) has announced that it will be increasing its dividend from last year's comparable payment on...
ZacksAbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag
The FDA grants breakthrough therapy designation to AbbVie's (ABBV) Epkinly in follicular lymphoma indication. The EMA validates a regulatory filing seeking label expansion for the drug.
- PR Newswire
AbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
AbbVie (NYSE: ABBV) today announced updates from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for epcoritamab, an investigational T-cell engaging bispecific antibody administered subcutaneously, for relapsed or refractory (R/R) follicular lymphoma (FL).
© 2023 Yahoo. All rights reserved.